CellCarta and Imagene AI Expanded Diagnostics Partnership
The two firms have extended their collaboration to accelerate AI-powered biomarker development for global pharmaceutical partners.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Should artificial intelligence be more widely used to develop new medical diagnostic tests?
CellCarta and Imagene AI have expanded their existing partnership focused on developing AI-powered companion diagnostics. The collaboration combines Imagene AI's predictive assay capabilities with CellCarta's clinical trial and regulatory infrastructure to support drug development programs.
Why it matters
Pharmaceutical firms increasingly require a scalable path to translate complex AI biomarker research into validated clinical assays. This partnership offers a comprehensive framework that spans from initial biomarker strategy through to regulatory readiness and trial execution.
The partnership currently supports AI-powered biomarker programs for 2 global pharmaceutical companies. Development includes programs applying the Lung Prediction Panel for non-small cell lung cancer, which currently functions as a Research Use Only tool.
The players
CellCarta
This company provides specialized laboratory services, clinical trial infrastructure, and regulatory expertise to the global pharmaceutical and biotechnology industries.
Imagene AI
This firm specializes in AI-powered assay development and biomarker prediction using histology images for oncology applications.
The details
The expanded collaboration utilizes Imagene AI's ability to extract biomarker predictions directly from H&E whole-slide images. CellCarta provides the necessary laboratory and regulatory support to integrate these AI-derived insights into standardized diagnostic workflows for clinical trials.
Timeline
The collaboration expansion was formally announced on October 2, 2026.
The Big Picture
The expansion follows the industry trend of integrating Imagene AI's Lung Prediction Panel into clinical trials to standardize biomarker detection. This partnership formalizes the operational pipeline necessary to scale the deployment of the panel from research into clinical development.
This collaboration aims to speed up the delivery of precision oncology treatments by simplifying the diagnostic development process. Patients may eventually benefit from faster enrollment in clinical trials and more accurate biomarker-based screening for lung cancer.
The takeaway
The integration of AI-driven diagnostics into clinical trial design represents a growing shift toward more efficient, data-backed drug development. Such partnerships help shorten the gap between a new scientific discovery in biomarker research and its practical application in patient care.
Further reading
For more on the latest developments in medical innovation, visit our /tech/biotech/ section.
Source note: This article includes information reported by Selectscience.
Live Poll
Should artificial intelligence be more widely used to develop new medical diagnostic tests?
